These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33904111)

  • 1. A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs.
    Sarpatwari A; Mitra-Majumdar M; Bykov K; Avorn J; Woloshin S; Toyserkani GA; LaCivita C; Manzo C; Zhou EH; Pinnow E; Dal Pan GJ; Gagne JJ; Huybrechts KF; Feldman WB; Chin K; Kesselheim AS
    Drug Saf; 2021 Jul; 44(7):743-751. PubMed ID: 33904111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use.
    Sarpatwari A; Brown BL; McGraw SA; Dejene SZ; Abdurrob A; Santiago Ortiz AJ; Kesselheim AS
    JAMA Netw Open; 2022 Jan; 5(1):e2144386. PubMed ID: 35050352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program - Current Status and Future Direction.
    Wu J; Juhaeri J
    Clin Ther; 2016 Dec; 38(12):2526-2532. PubMed ID: 27914632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014-2018) Using RE-AIM.
    Toyserkani GA; Huynh L; Morrato EH
    Front Public Health; 2020; 8():43. PubMed ID: 32158741
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.
    Shane R
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S6-S12. PubMed ID: 19966079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA Risk Evaluation and Mitigation Strategies (REMS) (2014-2018).
    Huynh L; Toyserkani GA; Morrato EH
    BMC Health Serv Res; 2021 Aug; 21(1):779. PubMed ID: 34362367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the quality of drug safety information for patients: An analysis of REMS educational materials.
    Chan HW; Russell AM; Smith MY
    Pharmacoepidemiol Drug Saf; 2018 Sep; 27(9):969-978. PubMed ID: 30003610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use.
    Sarpatwari A; Brown BL; McGraw SA; Dejene SZ; Abdurrob A; Kesselheim AS
    PLoS One; 2023; 18(7):e0288008. PubMed ID: 37410756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians.
    Sarpatwari A; Lu Z; Russo M; Zakoul H; Lee SB; Toyserkani GA; Zhou EH; LaCivita C; Shaw KHH; Zendel L; Dal Pan GJ; Kesselheim AS
    Clin Pharmacol Ther; 2024 Jun; 115(6):1293-1303. PubMed ID: 38375585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications.
    Meyer BM
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S3-5. PubMed ID: 19966078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APhA 2011 REMS white paper: Summary of the REMS stakeholder meeting on improving program design and implementation.
    American Pharmacists Association ; Bough M
    J Am Pharm Assoc (2003); 2011; 51(3):340-58. PubMed ID: 21555285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A Review.
    Heyward J; Olson L; Sharfstein JM; Stuart EA; Lurie P; Alexander GC
    JAMA Intern Med; 2020 Feb; 180(2):301-309. PubMed ID: 31886822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation and Use of Risk Evaluation and Mitigation Strategies Programs in Practice: A Scoping Review of the Literature.
    Tajchman S; Lawler B; Spence N; Haque S; Quintana Y; Ateya M
    Appl Clin Inform; 2022 Oct; 13(5):1151-1160. PubMed ID: 36482261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Evaluation and Mitigation Strategies (REMSs): Are They Improving Drug Safety? A Critical Review of REMSs Requiring Elements to Assure Safe Use (ETASU).
    Boudes PF
    Drugs R D; 2017 Jun; 17(2):245-254. PubMed ID: 28160230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Risk Evaluation and Mitigation Strategy (REMS) Public Dashboard: Improving Transparency of Regulatory Activities.
    Toyserkani GA; Lee JH; Zhou EH
    Pharmaceut Med; 2023 Sep; 37(5):349-353. PubMed ID: 37421560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products.
    Rollman JE; Heyward J; Olson L; Lurie P; Sharfstein J; Alexander GC
    JAMA; 2019 Feb; 321(7):676-685. PubMed ID: 30778596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk evaluation and mitigation strategies (REMS): educating the prescriber.
    Nicholson SC; Peterson J; Yektashenas B
    Drug Saf; 2012 Feb; 35(2):91-104. PubMed ID: 22171604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Turalio risk evaluation and mitigation strategy for treatment of tenosynovial giant cell tumor: framework and experience.
    Dharmani C; Wang E; Salas M; McCabe C; Diggs A; Choi Y; Jiang J; Keedy VL
    Future Oncol; 2022 Apr; 18(13):1595-1607. PubMed ID: 35105158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders.
    Johnson PE; Dahlman G; Eng K; Garg R; Gottlieb S; Hoffman JM; Howell P; Jahanzeb M; Johnson S; Mackler E; Rubino M; Sarokhan B; Marc Stewart F; Tyler T; Vose JM; Weinstein S; Li EC; Demartino J;
    J Natl Compr Canc Netw; 2010 Sep; 8 Suppl 7():S7-S27. PubMed ID: 20947724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.